Silence Therapeutics (SLN) EBITDA (2024 - 2026)

Silence Therapeutics has reported EBITDA for 3 years, with the latest figure at -$15.7 million in Q1 2026.

• Quarterly EBITDA rose 44.61% year-over-year to -$15.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$78.4 million (up 8.99% YoY) and the FY2025 annual result came in at -$91.1 million, down 43.84% from the prior year.
• EBITDA retreated to -$15.7 million in Q1 2026 per SLN's latest filing, from -$12.5 million in the prior quarter.
• Over five years, EBITDA peaked at -$4.4 million in Q4 2024 and troughed at -$30.0 million in Q3 2024.
• A 3-year average of -$18.9 million and a median of -$23.4 million in 2024 frame the typical range for EBITDA.
• The sharpest annual moves came in 2025 and 2026: EBITDA plunged 409.03% in 2025, then soared 44.61% in 2026.
• Over 3 years, EBITDA stood at -$4.4 million in 2024, then tumbled by 186.33% to -$12.5 million in 2025, then retreated by 26.29% to -$15.7 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$15.7 million, -$12.5 million, and -$26.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.